HealthONE

Denver, Colorado 80218

1 studies enrolling now · 5 studies all time

What they study most

Advanced Breast Cancer, Anogenital Cancer, BRCA-Associated Breast Carcinoma, BRCA-Mutated Ovarian Carcinoma, BRCA1 Mutation, Breast Cancer, Cervical Squamous Cell Carcinoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms, Cutaneous Squamous Cell Carcinoma (CSCC), ER+ Breast Cancer, HER2-negative Breast Cancer, HRD Positive Advanced Ovarian Cancer

Studies at this site

• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — Recruiting now
• A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy — Stopped early
• Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications — Stopped early
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface — Completed
• Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors — Stopped early